"Last week, when the Treasury effectively scuttled the Pfizer-Allergan merger, there was much rejoicing: Politicians and pundits alike were thrilled that tax inversion greed had been stopped, and that companies like Pfizer would have to 'pay their fair share.' "

Read the article